JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Chris Linthwaite, President and CEO, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 9:20 am ET in Boston, Massachusetts. The live audio webcast of the company’s presentation and subsequent replay may be accessed at http://wsw.com/webcast/cowen38/fldm. The webcast will be archived for 90 days following the live presentation.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single-cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are registered trademarks of Fluidigm Corporation.
Contact: Fluidigm Corporation Ana Petrovic Director, Corporate Development and Investor Relations 650 243 6628 (office) [email protected]
